ARTICLESInsights Into the Pathophysiology and Management of Dermatologic Toxicities to EGFR-Targeted Therapies in Colorectal CancerLacouture, Mario E. MDAuthor Information From the Cancer Skin Care Program and SERIES Clinic, Department of Dermatology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Ill. Financial Disclosure: Mario E. Lacouture, MD, is on the speaker bureau for Abbott Laboratories; Genentech, Inc.; ImClone Systems Incorporated; OSI Pharmaceuticals; and Onyx Pharmaceuticals, Inc. He is a consultant for Amgen, Bayer Healthcare Corporation, GlaxoSmithKline, and Bristol-Myers Squibb Company. This educational activity was supported by an educational grant from Bristol-Myers Squibb Company & ImClone Systems Incorporated. Corresponding author: Mario E. Lacouture, MD, Cancer Skin Care Program and SERIES Clinic, Department of Dermatology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 676 North St Clair Suite 1600, Chicago, IL 60611-2941 (e-mail: [email protected]). Accepted for publication April 13, 2007. Cancer Nursing: July 2007 - Volume 30 - Issue 4 - p S17-S26 doi: 10.1097/01.NCC.0000281758.85704.9b Buy Metrics Abstract Epidermal growth factor receptors (EGFRs) play an important role in the development of the skin and up-regulation of these receptors is associated with many cancer-related processes, such as inhibition of apoptosis and uncontrolled cell proliferation. Accordingly, treatment of metastatic colorectal cancer with EGFR inhibitors may lead to adverse cutaneous effects that can decrease the patient's quality of life and could possibly lead to reduced, interrupted, or discontinued therapy. Effective management of these adverse effects may lessen the chance of suboptimal therapy and requires an understanding of the underlying pathophysiology, as well as knowledge of useful strategies for alleviating these effects. © 2007 Lippincott Williams & Wilkins, Inc.